Stay updated on Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for a Phase 2 study of nivolumab, tadalafil, and oral vancomycin is displayed, including eligibility, treatment, outcomes, and results information. The record states that the study was terminated due to poor accrual.SummaryDifference70%

- Check16 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2. The study record remains inaccessible behind a 403 Forbidden page.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces NIH website transition updates and says that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label was updated from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1; the page continues to show a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details, indicating access to the record is blocked. A minimal Home option is shown in the footer, reflecting the restricted access state.SummaryDifference22%

Stay in the know with updates to Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page.